"Without longitudinal charts for the OLE endpoints, it leaves open the possibility that there was no absolute improvement in trajectory for early cohort's ADL, just relative separation between cohorts. Let's see if we get a clearer picture at the PD/AD conf, though I suspect it's not coming."
Let's say that "there was no absolute improvement in trajectory for early cohort's ADL, just relative separation between cohorts" is true and the company does not present data to the contrary. How important is that, to you, relative to the Mab's performance as you know it? How important do you think, it is to the EMA? TIA.
IMHO
Market Data 
Markets 
AI
